Literature DB >> 30088097

Formulation of Natural Oil Nano-Emulsions for the Topical Delivery of Clofazimine, Artemisone and Decoquinate.

Cornel Burger1, Marique Aucamp1, Jan du Preez1, Richard K Haynes1, Andile Ngwane2, Jeanetta du Plessis1, Minja Gerber3.   

Abstract

PURPOSE: The aim of this study was to formulate nano-emulsions comprising natural oils and the active pharmaceutical ingredients (APIs) clofazimine (CLF), artemisone (ATM) and decoquinate (DQ) in order to determine effectiveness of the nano-emulsions for topical delivery of the APIs. The APIs alone do not possess suitable physicochemical properties for topical drug delivery.
METHODS: Nano-emulsions were formulated with olive and safflower oils encapsulating the APIs. Skin diffusion and tape stripping studies were performed. By using the lactate dehydrogenase (LDH) assay, in vitro toxicity studies were carried out on immortalized human keratinocytes (HaCaT) cell line to determine cytotoxicities due to the APIs and the nano-emulsions incorporating the APIs.
RESULTS: The nano-emulsions were effective in delivering the APIs within the stratum corneum-epidermis and the epidermis-dermis, were non-cytotoxic towards HaCaT cell lines (p < 0.05) and inhibited Mycobacterium tuberculosis in vitro.
CONCLUSION: Natural oil nano-emulsions successfully deliver CLF, ATM and DQ and in principle could be used as supplementary topical treatment of cutaneous tuberculosis (CTB). Graphical Abstract ᅟ.

Entities:  

Keywords:  artemisone; clofazimine; cutaneous tuberculosis; decoquinate; nano-emulsions

Mesh:

Substances:

Year:  2018        PMID: 30088097     DOI: 10.1007/s11095-018-2471-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

1.  Reservoir function of the stratum corneum: development of an in vivo method to quantitatively determine the stratum corneum reservoir for topically applied substances.

Authors:  A Teichmann; U Jacobi; H-J Weigmann; W Sterry; J Lademann
Journal:  Skin Pharmacol Physiol       Date:  2005 Mar-Apr       Impact factor: 3.479

Review 2.  Advanced progress of microencapsulation technologies: in vivo and in vitro models for studying oral and transdermal drug deliveries.

Authors:  P L Lam; R Gambari
Journal:  J Control Release       Date:  2014-01-10       Impact factor: 9.776

3.  Development and validation of the simultaneous determination of artemisone, clofazimine and decoquinate with HPLC.

Authors:  J L du Preez; M E Aucamp; C Burger; M Gerber; J M Viljoen; L van Zyl; J du Plessis
Journal:  Pharmazie       Date:  2018-03-05       Impact factor: 1.267

4.  Protective effect of (2'S)-columbianetin from Corydalis heterocarpa on UVB-induced keratinocyte damage.

Authors:  Byul-Nim Ahn; Jung-Ae Kim; Chang-Suk Kong; Youngwan Seo; Se-Kwon Kim
Journal:  J Photochem Photobiol B       Date:  2012-01-12       Impact factor: 6.252

Review 5.  Cutaneous tuberculosis overview and current treatment regimens.

Authors:  Lindi van Zyl; Jeanetta du Plessis; Joe Viljoen
Journal:  Tuberculosis (Edinb)       Date:  2014-12-25       Impact factor: 3.131

6.  Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.

Authors:  Ildiko R Dunay; Wing Chi Chan; Richard K Haynes; L David Sibley
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

7.  Treatment of murine cerebral malaria by artemisone in combination with conventional antimalarial drugs: antiplasmodial effects and immune responses.

Authors:  W Armand Guiguemde; Nicholas H Hunt; Jintao Guo; Annael Marciano; Richard K Haynes; Julie Clark; R Kiplin Guy; Jacob Golenser
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor.

Authors:  Tae-Gyu Nam; Case W McNamara; Selina Bopp; Neekesh V Dharia; Stephan Meister; Ghislain M C Bonamy; David M Plouffe; Nobutaka Kato; Susan McCormack; Badry Bursulaya; Hangjun Ke; Akhil B Vaidya; Peter G Schultz; Elizabeth A Winzeler
Journal:  ACS Chem Biol       Date:  2011-09-08       Impact factor: 5.100

9.  Evaluation of Stability and In Vitro Security of Nanoemulsions Containing Eucalyptus globulus Oil.

Authors:  Samantha Nunes de Godoi; Priscilla Maciel Quatrin; Michele Rorato Sagrillo; Kátia Nascimento; Roger Wagner; Bruna Klein; Roberto Christ Vianna Santos; Aline Ferreira Ourique
Journal:  Biomed Res Int       Date:  2017-06-11       Impact factor: 3.411

Review 10.  Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum.

Authors:  Ahlam Zaid Alkilani; Maelíosa T C McCrudden; Ryan F Donnelly
Journal:  Pharmaceutics       Date:  2015-10-22       Impact factor: 6.321

View more
  5 in total

1.  Nanomedicines for Infectious Diseases.

Authors:  Admire Dube
Journal:  Pharm Res       Date:  2019-03-11       Impact factor: 4.200

Review 2.  Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?

Authors:  Luíse L Chaves; Yuri Patriota; José L Soares-Sobrinho; Alexandre C C Vieira; Sofia A Costa Lima; Salette Reis
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

3.  Efficient Treatment of Experimental Cerebral Malaria by an Artemisone-SMEDDS System: Impact of Application Route and Dosing Frequency.

Authors:  Karsten Mäder; Jacob Golenser; Johanna Zech; Nadeen Salaymeh; Nicholas H Hunt
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 4.  Chemical and Pharmacological Properties of Decoquinate: A Review of Its Pharmaceutical Potential and Future Perspectives.

Authors:  Tainá Santos Souza; Diogo Rodrigo Magalhães Moreira; Henrique Rodrigues Marcelino
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525

5.  The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria.

Authors:  Daniel J Watson; Lizahn Laing; Richard M Beteck; Liezl Gibhard; Richard K Haynes; Lubbe Wiesner
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.